We give you access to a high-quality pipeline of pharma-relevant healthtech startups. You co-select ventures, invest directly, and help shape their development — with no carry, no pooling, and no equity or fees to DayOne.

Investments are structured through convertible notes, offering downside protection and upside potential. Investors choose which startups to back and help shape the long-term support plans. The Basel ecosystem is an exceptional launchpad for R&D-driven ventures, offering access to customers, labs, talent, infrastructure and strategic exit opportunities. Our engagement continues beyond investment, with tailored mentorship, non-dilutive funding, network access, space at Switzerland Innovation Park and additional resources to support startups as they grow into valuable life science partners.

We ask for a soft commitment of CHF 250,000 per year. It’s non-binding and flexible:

• If unused, it rolls over to the next cohort
• After two cohorts without investment, we review the partnership

No. You invest only in the startups you choose. Your soft commitment ensures we can give startups confidence that funding is likely — but the decision is always yours.

Yes. CHF 250K is a baseline. You’re welcome to invest more in one or multiple startups depending on your interest and conviction.

1. You sign a partner agreement 
2. You join the selection committee (with pharma experts) 
3. You help select the top 15 startups for the accelerator 
4. After 4 months, 3 startups enter the post-accelerator 
5. You invest directly using our legal templates (or your own, with limited support) 

We offer Swiss-compliant convertible loan and equity term sheet templates. These are founder-friendly but investor-aligned.
If you want to lead a deal on your own terms, you are free to do so — we just may not coordinate the legal process if it differs from our structure.

No. DayOne is a non-profit and takes no equity, no fees, and no carry. We provide infrastructure, support, and coordination — but all investment goes directly between you and the startup.

DayOne acts as a facilitator and strategic matchmaker – connecting investors and industry partners with a curated selection of high-potential healthtech startups poised for market traction. Leveraging deep sector expertise and a clear understanding of industry challenges, we create streamlined, lower-risk investment and co-investment opportunities tailored for long-term impact.

Pharma experts sit on the selection committee and support the ventures throughout. Their involvement ensures startups address real industry problems and gain strategic visibility.

Startups selected for the post-accelerator and receiving your investment get a CHF 50K non-dilutive grant, if they also establish a presence in the Basel Area. This boosts runway and de-risks your investment.

Startups that enable or accelerate pharmaceutical R&D:

• Digital health, techbio, AI/ML for drug discovery or trials
• Diagnostics, decision-support tools, data platforms
• IP-protected or early-traction companies
  All are selected from a global funnel and vetted by both investors and pharma.